Robert Kramer - 23 Feb 2022 Form 4 Insider Report for Emergent BioSolutions Inc. (EBS)

Reporting relationship
President and CEO, Director
Issuer ticker
EBS
Reported as of
23 Feb 2022
Net transaction value
-$146,308
Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
25 Feb 2022, 16:18:00 UTC
Prior SEC filing
24 Feb 2022
Next SEC filing
02 Mar 2022
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ S. Scott Lieberman, Attorney-in-fact

Key filing fact

Robert Kramer filed Form 4 for Emergent BioSolutions Inc. (EBS) on 25 Feb 2022.

Key facts

  • This page summarizes Robert Kramer's Form 4 filing for Emergent BioSolutions Inc. (EBS).
  • 2 reported transactions and 0 derivative rows are listed below.
  • Accepted by SEC: 25 Feb 2022, 16:18.

Change

  • Previous filing in this sequence was filed on 24 Feb 2022.
  • Current net transaction value: -$146,308.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

EBS transaction

Common Stock

Tax liability

Transaction value
$59,924
Shares
-1,419
Change %
-0.87%
Price
$42.23
Shares after
161,303
Date
23 Feb 2022
Ownership
Direct
Footnotes
F1
EBS transaction

Common Stock

Tax liability

Transaction value
$86,384
Shares
-2,034
Change %
-1.3%
Price
$42.47
Shares after
159,269
Date
24 Feb 2022
Ownership
Direct
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents shares of common stock withheld by the Company in exchange for payment of the employee's withholding taxes.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .